Shire slides after it withdraws US drug licence application - UPDATE
Pharmaceuticals firm Shire has withdrawn its licence application for the Fabry disease treatment, REPLAGAL, with the US Food and Drug Administration (FDA).
Pharmaceuticals firm Shire has withdrawn its licence application for the Fabry disease treatment, REPLAGAL, with the US Food and Drug Administration (FDA).
Fabry disease is a rare enzyme deficiency condition which can result in "full body" pain and kidney failure.
Shire says the FDA encouraged it to submit an application, with the implication being that approval could be fast tracked.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The company now says recent communication with the agency has suggested further controlled trials would be required before a licence could be granted, the costs of which Shire seems unwilling to take on.
REPLAGAL has been cleared for use in the European Union for 10 years.
The news saw Shire shares drop 1.66% by 11:46.
In a separate announcement Dublin based Shire said it would buy the Californian firm Ferrokin Biosciences for an upfront payment of $100m, payable in cash at closing, plus potential post-closing milestone payments of up to $225m.
The transaction will give Shire control over FerroKin's FBS0701. It may not be the most snappily named drug but can be easily described as a once-a-day oral capsule for the treatment of iron overload due to chronic blood transfusions.
BS
-
FTSE 100 hits record highs – why is it rising and will we see more gains?
Advice UK equities have been described as unloved for a long time but as the FTSE 100 hits new highs, we explain if now is the time to buy British.
By Marc Shoffman Published
-
How to invest in copper
It may be time to invest in copper as the red metal appears poised for a big jump. Dominic Frisby looks at what should investors should buy
By Dominic Frisby Published